J Biol Chem. 2017 Mar 20. pii: jbc.M116.767384. doi: 10.1074/jbc.M116.767384.
[Epub ahead of print]
Chanda D1, Oligschlaeger Y2, Geraets I2, Liu Y2, Zhu X2, Li J2, Nabben M2, Coumans W2, Luiken JJ2, Glatz JF2, Neumann D2.
Abstract
Several studies have linked impaired glucose uptake and insulin resistance (IR) to functional impairment of the heart. Recently, endocannabinoids have been implicated in cardiovascular disease. However, the mechanisms involving endocannabinoid signaling, glucose uptake and IR in cardiomyocytes are understudied. Here, we report the endocannabinoid 2-Arachidonoylglycerol (2-AG) via stimulation of cannabinoid type-1 (CB1) receptor and Ca2+/Calmodulin-dependent protein kinase β (CaMKKβ) activates AMPK leading to increased glucose uptake. Interestingly, we have observed that the mRNA expression of CB1 and CB2 receptors was decreased in diabetic mice, indicating reduced endocannabinoid signaling in diabetic heart. We further establish that TNFα induces IR in cardiomyocytes. Treatment with 2-AG suppresses TNFα-induced pro-inflammatory markers, and improves IR and glucose uptake. Conversely, pharmacological inhibition or knockdown of AMPK attenuates the anti-inflammatory effect and reversal of IR elicited by 2-AG. Additionally, in human embryonic stem cell-derived cardiomyocytes challenged with TNFα or free fatty acid (FFA), we demonstrate that 2-AG improves insulin sensitivity and glucose uptake. In conclusion, 2-AG abates inflammatory responses, increases glucose uptake and overcomes IR in an AMPK-dependent manner in cardiomyocytes.
Copyright © 2017, The American Society for Biochemistry and Molecular Biology.
KEYWORDS:
AMP-activated kinase (AMPK); cell signaling; endocannabinoid; glucose transporter type 4 (GLUT4); glucose uptake; inflammation; insulin resistance
- PMID: 28320859
- DOI: 10.1074/jbc.M116.767384